Idelalisib (Zydelig▼): updated safety information on risk of infection

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

An EU safety review of idelalisib in March 2016 identified a risk of serious infection associated with idelalisib, following which temporary safety measures were formulated and communicated in May 3016

After the conclusion of the safety review of idelalisib in July 2016, updated treatment recommendations have been released. (See...